ATE207459T1 - O-malonyltyrosyl-verbindungen, o-malonyltyrosyl- verbindungen enthaltende peptide und ihre verwendung - Google Patents

O-malonyltyrosyl-verbindungen, o-malonyltyrosyl- verbindungen enthaltende peptide und ihre verwendung

Info

Publication number
ATE207459T1
ATE207459T1 AT96910637T AT96910637T ATE207459T1 AT E207459 T1 ATE207459 T1 AT E207459T1 AT 96910637 T AT96910637 T AT 96910637T AT 96910637 T AT96910637 T AT 96910637T AT E207459 T1 ATE207459 T1 AT E207459T1
Authority
AT
Austria
Prior art keywords
malonyltyrosyl
compounds
compound
peptides
present
Prior art date
Application number
AT96910637T
Other languages
English (en)
Inventor
Terrence R Burke Jr
Bin Ye
Miki Akamatsu
Hemanta K Kole
Xinjian Yan
Peter R Roller
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE207459T1 publication Critical patent/ATE207459T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
    • C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
    • C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
    • C07C2603/18—Fluorenes; Hydrogenated fluorenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96910637T 1995-03-31 1996-03-29 O-malonyltyrosyl-verbindungen, o-malonyltyrosyl- verbindungen enthaltende peptide und ihre verwendung ATE207459T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/414,520 US5688992A (en) 1995-03-31 1995-03-31 O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
PCT/US1996/004311 WO1996030332A1 (en) 1995-03-31 1996-03-29 O-malonyltyrosyl compounds, o-malonyltyrosyl compound-containing peptides, and uses thereof

Publications (1)

Publication Number Publication Date
ATE207459T1 true ATE207459T1 (de) 2001-11-15

Family

ID=23641810

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910637T ATE207459T1 (de) 1995-03-31 1996-03-29 O-malonyltyrosyl-verbindungen, o-malonyltyrosyl- verbindungen enthaltende peptide und ihre verwendung

Country Status (8)

Country Link
US (1) US5688992A (de)
EP (1) EP0820433B1 (de)
JP (1) JP3929490B2 (de)
AT (1) ATE207459T1 (de)
AU (1) AU708929B2 (de)
CA (1) CA2215827C (de)
DE (1) DE69616303T2 (de)
WO (1) WO1996030332A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119029A0 (en) * 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5994522A (en) * 1997-01-24 1999-11-30 Washington University BLNK proteins
US6410585B1 (en) * 1997-08-28 2002-06-25 Scott D. Larsen Inhibitors of protein tyrosine phosphatase
WO1999011606A2 (en) * 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
US6156784A (en) * 1997-12-18 2000-12-05 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as phosphotyrosine mimics
CA2345459A1 (en) 1998-11-12 2000-05-18 Regine Bohacek Bicyclic signal transduction inhibitors, compositions containing them & uses thereof
US6307090B1 (en) 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
AU770920C (en) * 1999-03-23 2004-10-07 Georgetown University Phenylalanine derivatives
US7226991B1 (en) * 1999-03-23 2007-06-05 United States Of America, Represented By The Secretary, Department Of Health And Human Services Phenylalanine derivatives
EP1171113B1 (de) * 1999-04-15 2004-06-02 Boehringer Ingelheim Pharmaceuticals, Inc. Verbindungen zur verwendung als phosphotyrosinmimetika
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
ATE362767T1 (de) 1999-10-22 2007-06-15 Us Gov Health & Human Serv Hemmung der zellmotilität und angiogenese mit grb2 sh2-domäne inhibitoren
CA2419870A1 (en) * 2000-08-22 2002-02-28 Yang Gao Sh2 domain binding inhibitors
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US20040138104A1 (en) * 2003-01-14 2004-07-15 The Government Of The United States Of America Represented By The Secretary, Peptides
US20050119163A1 (en) 2003-09-18 2005-06-02 The Government Of The United States Of America, As Represented By The Secretary, SH2 domain binding inhibitors
JP6457999B2 (ja) * 2013-03-14 2019-01-23 ザ チルドレンズ メディカル センター コーポレーション 処置に関してがんの対象を識別するためのｃｄ３６の使用
IT202000004849A1 (it) * 2020-03-06 2021-09-06 Univ Degli Studi Di Roma “Tor Vergata” Peptidi e loro usi

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5200546A (en) * 1991-09-30 1993-04-06 The United States Of America As Represented By The Department Of Health And Human Services Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
US5264607A (en) * 1991-09-30 1993-11-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Process of making benzylic α,α-diflurophosphonates from benzylic α-ketophosphorates
WO1994007913A1 (en) * 1992-09-25 1994-04-14 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
WO1994008600A1 (en) * 1992-10-09 1994-04-28 Joslin Diabetes Center Inhibition of signal transduction molecules

Also Published As

Publication number Publication date
AU5377696A (en) 1996-10-16
DE69616303D1 (de) 2001-11-29
EP0820433A1 (de) 1998-01-28
EP0820433B1 (de) 2001-10-24
CA2215827A1 (en) 1996-10-03
JP3929490B2 (ja) 2007-06-13
AU708929B2 (en) 1999-08-19
CA2215827C (en) 2010-08-10
DE69616303T2 (de) 2004-08-12
JPH11505520A (ja) 1999-05-21
US5688992A (en) 1997-11-18
WO1996030332A1 (en) 1996-10-03

Similar Documents

Publication Publication Date Title
ATE207459T1 (de) O-malonyltyrosyl-verbindungen, o-malonyltyrosyl- verbindungen enthaltende peptide und ihre verwendung
IL100731A0 (en) Mixed specificity fusion protein and pharmaceutical composition containing it
CY1105654T1 (el) Εκλεκτικες ενωσεις για τον υποδοχεα της μελανοκορτινης 1
ATE206433T1 (de) Beta-schleifenähnliche verbindungen und deren verwendung als protease-inhibitoren
MX9603532A (es) Sistema de suministro de acido nucleico, metodo de sintesis y sus usos.
MX9709265A (es) Superantigenos modificados/quimericos y sus usos.
ATE348632T1 (de) Prion protein peptide und deren verwendung
AU6769998A (en) Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
ES2187946T3 (es) Uso de interleucina-15.
DE69326064D1 (de) Peptide des menschlichen Proteins P53 zum Gebrauch in menschlichen-zytotoxischen-T-Zell-Antwort-induzierenden Kompositionen sowie menschliche P53-Protein-spezifische T-Lymphocyten
CA2056279A1 (en) Cell-free receptor binding assays, the production and use thereof
DE69632815D1 (de) gC1q-REZEPTOR, DARAN BINDENDE HIV-1 gp120-REGION, VERWANDTE PEPTIDE UND ANTIKÖRPER
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
DE69737978D1 (de) Als 2f1 bezeichnetes rezeptorprotein
DE69736515D1 (de) Neue ortho-naphthochinonderivate, neue synthesen zu ihrer herstellung und ihre anwendung in der inhibierung von neoplastischem zellwachstum
FI964445A (fi) Komposiittimembraani kemiallista synteesiä varten
PT877803E (pt) Receptor da proteina ob e composicoes e metodos afins
NZ504240A (en) Soluble CD8 molecule as an inhibitor of the cellular immune system
AU2002316190A1 (en) p53 binding T cell receptor molecules and uses thereof
BR9611947A (pt) Isoindolonas fundidas como inibidores da quinase da proteina c
ATE207757T1 (de) Für die immun- und cns-therapie nutzbare, neuartige tripeptide
DE69631624D1 (de) Antikörper gegen menschliches restrictin
Reinherz Adhesion Molecules as Drug Targets. The Case of CD2
DE69535380D1 (de) Humaner kappa opiatrezeptor, nukleinsäuren und ihre verwendungen
DK0938555T3 (da) Konstruktioner og komplekser af cyclin E

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties